Vaborbactam (RPX7009) is a cyclic boronic acid pharmacophore β-lactamase inhibitor.

CAY10566 is a potent, orally bioavailable and selective inhibitor of stearoyl-CoA desaturase1 (SCD1) with IC50 of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. It also demonstrates excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells.

CAY10566 is a potent, orally bioavailable and selective inhibitor of stearoyl-CoA desaturase1 (SCD1) with IC50 of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. It also demonstrates excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells.

CAY10566 is a potent, orally bioavailable and selective inhibitor of stearoyl-CoA desaturase1 (SCD1) with IC50 of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. It also demonstrates excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells.

CAY10566 is a potent, orally bioavailable and selective inhibitor of stearoyl-CoA desaturase1 (SCD1) with IC50 of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. It also demonstrates excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells.

Brensocatib (AZD7986, INS1007) is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1). It reduces the activity of all major neutrophil serine proteases (NSPs) including, neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in patients with bronchiectasis.

Brensocatib (AZD7986, INS1007) is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1). It reduces the activity of all major neutrophil serine proteases (NSPs) including, neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in patients with bronchiectasis.

Tenapanor (AZD1722, RDX5791) is a potent and orally active inhibitor of sodium/hydrogen exchanger isoform 3 (NHE3). It exhibits an IC50 of 2 and 6 nM in human and mouse ileum monolayers, respectively. Tenapanor reduces intestinal phosphate absorption predominantly by reducing passive paracellular phosphate flux.

Brensocatib (AZD7986, INS1007) is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1). It reduces the activity of all major neutrophil serine proteases (NSPs) including, neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in patients with bronchiectasis.

Brensocatib (AZD7986, INS1007) is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1). It reduces the activity of all major neutrophil serine proteases (NSPs) including, neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in patients with bronchiectasis.